Extreme intense respiratory disorder coronavirus 2 (SARS-CoV-2), the infection that causes coronavirus illness 2019 (Covid-19), has created an overall pandemic. The interference of its spread relies upon a blend of pharmacologic and nonpharmacologic intercessions. Beigel., et al. have given in the Journal the principal report of a powerful treatment for Covid-19, coming about because of a thoroughly structured and led clinical trial [1].

It is surprising that a randomized, fake treatment controlled preliminary of a possible antiviral treatment for an infection whose pathogenesis is as yet not completely characterized was done at numerous global locales during a pandemic.

References

1. Beigel JH., et al. “Remdesivir for the treatment of Covid-19 — preliminary report”. The New England Journal of Medicine (2020).
2. FDA issuance of emergency use authorization for potential COVID-19 treatment. Press release of the Food and Drug Administration (2020).
3. Goldman JD., et al. “Remdesivir for 5 or 10 days in patients with severe Covid-19”. The New England Journal of Medicine (2020).
4. Guan W., et al. “Clinical characteristics of coronavirus disease 2019 in China”. The New England Journal of Medicine 382 (2020): 1708-1720.
5. Mehta P., et al. “COVID-19: consider cytokine storm syndromes and immunosuppression”. Lancet 395 (2020): 1033-1034.
6. Cohen MS and Corey L. “Combination prevention for COVID-19”. Science 368 (2020): 551.
7. Rolain J-M., et al. “Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century”. International Journal of Antimicrobial Agents 30 (2007): 297-308.
8. Yao T-T., et al. “A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus — a possible reference for coronavirus disease-19 treatment option”. Journal of Medical Virology 92 (2020): 556-563.
9. Hernandez AV., et al. “Hydroxychloroquine or chloroquine for treatment or prophylaxis of COVID-19: a living systematic review”. Annals of Internal Medicine (2020).
10. Boulware DR., et al. “A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19”. The New England Journal of Medicine (2020).
11. Tostmann A., et al. “Strong associations and moderate predictive value of early symptoms for SARSCoV-2 test positivity among healthcare workers, the Netherlands, March 2020”. Euro Surveillance 25.16 (2020): 2000508.
12. Wu Z and McGoogan JM. “Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention”. JAMA (2020).
13. Sheahan TP., et al. “An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice”. Science Translational Medicine 12.541 (2020): eabb5883.
14. Magagnoli J., et al. “Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19” (2020). 
15. Sayare S. “He was a science star. Then he promoted a questionable cure for COVID-19”. New York Times Magazine (2020).

Citation

Citation: Indranil Chatterjee., et al. “Remdesivir and Hydroxychloroquine: An Important First Step of Searching for Evidence to Prevent COVID-19 (SARS-CoV-2)". Acta Scientific Microbiology 3.9 (2020): 23-26.

Copyright

Copyright: © 2020 Indranil Chatterjee., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.